

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Human Rho D Immune Globulin
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
PRIVIGEN Granted Orphan-Drug Designation
Details : CSL Behring advances Ig clinical trial program to address need in treating serious autoimmune disease.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
February 11, 2020
Lead Product(s) : Human Rho D Immune Globulin
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
